SRR1343879
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.427
- INFLAMMATORY_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.382
- IL6_JAK_STAT3_SIGNALING+0.350
- ANGIOGENESIS+0.332
- ALLOGRAFT_REJECTION+0.318
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.313
- MYOGENESIS+0.303
- APICAL_SURFACE+0.293
- KRAS_SIGNALING_DN+0.268
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.491
- MYC_TARGETS_V1-0.486
- MYC_TARGETS_V2-0.414
- PROTEIN_SECRETION-0.401
- DNA_REPAIR-0.396
- UNFOLDED_PROTEIN_RESPONSE-0.377
- E2F_TARGETS-0.356
- G2M_CHECKPOINT-0.336
- UV_RESPONSE_DN-0.329
- MITOTIC_SPINDLE-0.313
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1467590 | GTEX | — | 0.932 |
| 2 | SRR1120755 | GTEX | — | 0.917 |
| 3 | SRR612455 | GTEX | — | 0.914 |
| 4 | SRR1415832 | GTEX | — | 0.912 |
| 5 | SRR1317494 | GTEX | — | 0.911 |
| 6 | SRR1310623 | GTEX | — | 0.910 |
| 7 | SRR1468141 | GTEX | — | 0.903 |
| 8 | sclc55A_S50.txt | — | cohortMD2 | 0.900 |
| 9 | SRR1420625 | GTEX | — | 0.897 |
| 10 | SRR615020 | GTEX | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.427 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.382 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.332 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.318 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.313 | Inavolisib | — uncovered |
| MYOGENESIS | 0.303 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.293 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.268 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.265 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.264 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.208 | Inavolisib | — uncovered |
| COAGULATION | 0.207 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.199 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.192 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.168 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.138 | Inavolisib | — uncovered |
| HYPOXIA | 0.099 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.086 | Inavolisib | — uncovered |